JP2014519318A5 - - Google Patents

Download PDF

Info

Publication number
JP2014519318A5
JP2014519318A5 JP2014509819A JP2014509819A JP2014519318A5 JP 2014519318 A5 JP2014519318 A5 JP 2014519318A5 JP 2014509819 A JP2014509819 A JP 2014509819A JP 2014509819 A JP2014509819 A JP 2014509819A JP 2014519318 A5 JP2014519318 A5 JP 2014519318A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
antibody
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014509819A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014519318A (ja
JP6181043B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2012/051004 external-priority patent/WO2012153123A1/en
Publication of JP2014519318A publication Critical patent/JP2014519318A/ja
Publication of JP2014519318A5 publication Critical patent/JP2014519318A5/ja
Application granted granted Critical
Publication of JP6181043B2 publication Critical patent/JP6181043B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014509819A 2011-05-06 2012-05-08 抗神経成長因子抗体ならびにそれを調製および使用する方法 Active JP6181043B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161483491P 2011-05-06 2011-05-06
US61/483,491 2011-05-06
US201161531439P 2011-09-06 2011-09-06
US61/531,439 2011-09-06
PCT/GB2012/051004 WO2012153123A1 (en) 2011-05-06 2012-05-08 Anti-nerve growth factor antibodies and methods of preparing and using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017075108A Division JP6526089B2 (ja) 2011-05-06 2017-04-05 抗神経成長因子抗体ならびにそれを調製および使用する方法

Publications (3)

Publication Number Publication Date
JP2014519318A JP2014519318A (ja) 2014-08-14
JP2014519318A5 true JP2014519318A5 (cg-RX-API-DMAC7.html) 2016-07-21
JP6181043B2 JP6181043B2 (ja) 2017-08-16

Family

ID=46168541

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014509819A Active JP6181043B2 (ja) 2011-05-06 2012-05-08 抗神経成長因子抗体ならびにそれを調製および使用する方法
JP2017075108A Active JP6526089B2 (ja) 2011-05-06 2017-04-05 抗神経成長因子抗体ならびにそれを調製および使用する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017075108A Active JP6526089B2 (ja) 2011-05-06 2017-04-05 抗神経成長因子抗体ならびにそれを調製および使用する方法

Country Status (14)

Country Link
US (2) US20140170136A1 (cg-RX-API-DMAC7.html)
EP (2) EP3502136A1 (cg-RX-API-DMAC7.html)
JP (2) JP6181043B2 (cg-RX-API-DMAC7.html)
KR (1) KR101833465B1 (cg-RX-API-DMAC7.html)
CN (1) CN103764677A (cg-RX-API-DMAC7.html)
AU (1) AU2012252153B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013028652A8 (cg-RX-API-DMAC7.html)
CA (1) CA2834983C (cg-RX-API-DMAC7.html)
ES (1) ES2704007T3 (cg-RX-API-DMAC7.html)
GB (1) GB2504888B (cg-RX-API-DMAC7.html)
MY (1) MY160884A (cg-RX-API-DMAC7.html)
RU (1) RU2640252C2 (cg-RX-API-DMAC7.html)
SG (2) SG10201500957QA (cg-RX-API-DMAC7.html)
WO (1) WO2012153123A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
NZ611076A (en) 2010-12-01 2015-09-25 Alderbio Holdings Llc Anti-ngf compositions and use thereof
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
WO2012153123A1 (en) * 2011-05-06 2012-11-15 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of preparing and using the same
AU2014368449C1 (en) 2013-12-20 2021-05-06 Intervet International B.V. Canine antibodies with modified CH2-CH3 sequences
CN107074952B (zh) 2014-09-30 2021-04-09 英特维特国际股份有限公司 结合犬pd-l1的pd-l1抗体
CN104774265B (zh) * 2015-02-12 2018-05-04 北京华安科创生物技术有限公司 抗人神经生长因子的中和性单克隆抗体11f1及其杂交瘤细胞株
CN104910274B (zh) * 2015-02-12 2018-05-04 北京华安科创生物技术有限公司 抗人神经生长因子的中和性单克隆抗体12c11及其杂交瘤细胞株
AR104721A1 (es) * 2015-05-22 2017-08-09 Astellas Pharma Inc Fragmento fab anti-ngf humano
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
EP3390451B1 (en) 2015-12-18 2025-01-22 Intervet International B.V. Caninized human antibodies to human and canine il-4r alpha
WO2019035010A1 (en) * 2017-08-15 2019-02-21 Kindred Biosciences, Inc. IGG VARIANTS FOR VETERINARY USE
GB2578867A (en) * 2018-10-09 2020-06-03 Genome Res Ltd Animal models and therapeutic molecules
FR3087107A1 (fr) 2018-10-15 2020-04-17 Avent Inc. Compositions, systèmes, kits et méthodes d'ablation neurale
WO2022087153A1 (en) * 2020-10-22 2022-04-28 Scout Bio, Inc. Method of suppressing immune response to vector-delivered therapeutic protein
KR20240006586A (ko) 2021-05-12 2024-01-15 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Rankl 및 ngf에 특이적으로 결합하는 항원 결합 분자, 및 이의 의학적 용도
CN118475612A (zh) 2021-08-31 2024-08-09 斯科特生物公司 抗原结合分子及其用途
WO2025036564A1 (de) * 2023-08-17 2025-02-20 Gottfried Wilhelm Leibniz Universität Hannover (Luh) Nukleinsäuresequenz, vektor, screening-verfahren und verfahren zur herstellung von rekombinanten antikörpern

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
FI903489A0 (fi) 1988-11-11 1990-07-10 Medical Res Council Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
AU632843B2 (en) * 1989-08-10 1993-01-14 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Cat-mouse heterohybridoma and gene fragment coding for constant region of feline immunoglobulin
CA2110799A1 (en) 1991-06-14 1992-12-23 Arnold H. Horwitz Microbially-produced antibody fragments and their conjugates
DE69233745D1 (de) 1991-12-02 2008-10-23 Cambridge Antibody Tech Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
ES2335861T3 (es) 2000-09-08 2010-04-06 Universitat Zurich Grupos de proteinas repetitivas que comprenden modulos repetitivos.
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
DK2206728T3 (en) * 2004-04-07 2018-04-23 Rinat Neuroscience Corp METHODS OF TREATING BONE CANCER PAIN BY SUBMITTING A NERVOUS FACTOR-ANTAGONISTIC ANTIBODY
ITRM20050290A1 (it) * 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
WO2007038619A2 (en) 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
WO2010027488A2 (en) * 2008-09-04 2010-03-11 Vet Therapeutics, Inc. Monoclonal antibodies
NZ596839A (en) 2009-05-04 2014-01-31 Abbott Res Bv Antibodies against nerve growth factor (ngf) with enhanced in vivo stability
BR112012022342A2 (pt) * 2010-03-04 2017-02-14 Vet Therapeutics Inc anticorpos monoclonais dirigidos a cd52
JP5911813B2 (ja) * 2010-03-04 2016-04-27 ベット・セラピューティクス・インコーポレイテッドVet Therapeutics Inc. Cd20に対するモノクローナル抗体
PT3333188T (pt) * 2010-08-19 2022-03-28 Zoetis Belgium S A Anticorpos de anti-ngf e a sua utilização
WO2012153123A1 (en) * 2011-05-06 2012-11-15 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of preparing and using the same

Similar Documents

Publication Publication Date Title
JP2014519318A5 (cg-RX-API-DMAC7.html)
JP2014519317A5 (cg-RX-API-DMAC7.html)
CN110191896B (zh) 改进的血清白蛋白结合物
JP7254699B2 (ja) 抗bcma重鎖のみ抗体
IL305912B1 (en) Improved serum albumin binders
EA201991099A1 (ru) Антитела против cd73 и их применение
JP2019147801A5 (cg-RX-API-DMAC7.html)
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
JP2018506277A5 (cg-RX-API-DMAC7.html)
JP2014522236A5 (cg-RX-API-DMAC7.html)
JP2013538057A5 (cg-RX-API-DMAC7.html)
JP2019535763A5 (cg-RX-API-DMAC7.html)
JP2018527919A5 (cg-RX-API-DMAC7.html)
JP2010526028A5 (cg-RX-API-DMAC7.html)
RU2018113505A (ru) Il-8-связывающие антитела и их применения
JP2016188209A5 (cg-RX-API-DMAC7.html)
RU2015143886A (ru) Антитела к тау и способы применения
RU2016100892A (ru) Антитела против tweakr и их применение
JP2016512551A5 (cg-RX-API-DMAC7.html)
RU2016137256A (ru) АНТИТЕЛА К ФАКТОРУ КОМПЛЕМЕНТА Bb
JP2019506841A5 (cg-RX-API-DMAC7.html)
RU2016129113A (ru) Антитела к pd-1 собак
JP2017522903A5 (cg-RX-API-DMAC7.html)
TR201817932T4 (en) ANTIBODIES THAT BIND STAPHYLOCOCCUS AUREUS ALPHA TOXIN SPECIFICALLY AND METHODS OF USE
JP2014526898A5 (cg-RX-API-DMAC7.html)